13G Filing: Park West Asset Management and Eagle Pharmaceuticals Inc. (EGRX)

 * Beneficial
ownership percentage is based upon 15,169,241 shares of common stock,
$0.001 par value per share (“Common Stock”), of Eagle Pharmaceuticals, Inc., a Delaware corporation (the “Company”),
issued and outstanding as of August 2, 2017, based on information reported by the Company in its Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission on August 9, 2017. Park West Asset Management LLC (“PWAM”) is the
investment manager to Park West Investors Master Fund, Limited, a Cayman Islands exempted company (“PWIMF”), and Park
West Partners International, Limited, a Cayman Islands exempted company (“PWPI” and, collectively with PWIMF, the
“PW Funds”), and Peter S. Park (“Mr. Park” and, collectively with PWAM, the “Reporting Persons”)
is the sole member and manager of PWAM. As of August 14, 2017, PWIMF held 697,739 shares of Common Stock and PWPI held 88,681
shares of Common Stock. As a result of the foregoing, for purposes of Reg. Section 240.13d-3, the Reporting Persons may be deemed
to beneficially own the 786,420 shares of Common Stock held in the aggregate by the PW Funds, or approximately 5.2% of the shares
of Common Stock deemed to be issued and outstanding as of August 14, 2017.